Real-world outcomes of lower lenvatinib doses in advanced neuroendocrine tumors: a multinational retrospective study

Objective: Neuroendocrine tumors (NET) are heterogeneous neoplasms with increasing incidence and limited treatment options for advanced, progressive disease. Lenvatinib, a multitargeted TKI, demonstrated high efficacy but substantial toxicity at the standard 24 mg/day in the phase II TALENT trial. T...

Full description

Bibliographic Details

Main Authors:	G R Almeida, G K Zanetta, J M O’Connor, M J Barros, T C Felismino, R F Weschenfelder, A Bel-Ange, S Grozinsky-Glasberg, P R Riechelmann
Format:	Artigo
Language:	Inglês
Published:	Bioscientifica 2025-12-01
Series:	Endocrine Oncology
Subjects:	neuroendocrine tumors metastasis carcinoids
Online Access:	https://eo.bioscientifica.com/view/journals/eo/5/1/EO-25-0076.xml
Tags:	Add Tag No Tags, Be the first to tag this record!